Video

Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ Cancer

Author(s):

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

It is known that Eastern and Western patients with gastric/GEJ cancer are different in terms of etiology of the gastric cancer and the outcome. Asian patients with gastric/GEJ cancer seem to survive longer, and are diagnosed at an earlier stage, compared with Western populations, says Chau. This is due to these patients being younger with less comorbidities.

In an analysis of cohorts from the ATTRACTION-2 and CheckMate-032 trials, investigators described the safety profile of nivolumab (Opdivo) in Asian and Western patients who had received 2 or more prior lines of chemotherapy. This population included patients who received more than 1 dose of nivolumab at the data cutoff of August 2016 for ATTRACTION-2 and March 2016 for CheckMate-032. Investigators aimed to answer the question of difference in outcomes between Eastern and Western patients with gastric/GEJ cancer when treated with immunotherapy.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS